Last reviewed · How we verify

oral sitagliptin supplementation

Ain Shams University · Phase 3 active Small molecule

oral sitagliptin supplementation is a DPP-4 inhibitor Small molecule drug developed by Ain Shams University. It is currently in Phase 3 development for Type 2 diabetes mellitus.

Sitagliptin works by inhibiting the enzyme dipeptidyl peptidase-4 (DPP-4), which breaks down incretin hormones.

Sitagliptin works by inhibiting the enzyme dipeptidyl peptidase-4 (DPP-4), which breaks down incretin hormones. Used for Type 2 diabetes mellitus.

At a glance

Generic nameoral sitagliptin supplementation
SponsorAin Shams University
Drug classDPP-4 inhibitor
TargetDPP-4
ModalitySmall molecule
Therapeutic areaDiabetes
PhasePhase 3

Mechanism of action

This leads to increased levels of incretin hormones, which in turn stimulate the release of insulin and decrease the release of glucagon, resulting in improved glycemic control. Sitagliptin does not stimulate insulin release or increase insulin sensitivity, but rather enhances the body's natural response to elevated glucose levels.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about oral sitagliptin supplementation

What is oral sitagliptin supplementation?

oral sitagliptin supplementation is a DPP-4 inhibitor drug developed by Ain Shams University, indicated for Type 2 diabetes mellitus.

How does oral sitagliptin supplementation work?

Sitagliptin works by inhibiting the enzyme dipeptidyl peptidase-4 (DPP-4), which breaks down incretin hormones.

What is oral sitagliptin supplementation used for?

oral sitagliptin supplementation is indicated for Type 2 diabetes mellitus.

Who makes oral sitagliptin supplementation?

oral sitagliptin supplementation is developed by Ain Shams University (see full Ain Shams University pipeline at /company/ain-shams-university).

What drug class is oral sitagliptin supplementation in?

oral sitagliptin supplementation belongs to the DPP-4 inhibitor class. See all DPP-4 inhibitor drugs at /class/dpp-4-inhibitor.

What development phase is oral sitagliptin supplementation in?

oral sitagliptin supplementation is in Phase 3.

What are the side effects of oral sitagliptin supplementation?

Common side effects of oral sitagliptin supplementation include Nausea, Diarrhea, Headache, Upper respiratory tract infection, Musculoskeletal pain.

What does oral sitagliptin supplementation target?

oral sitagliptin supplementation targets DPP-4 and is a DPP-4 inhibitor.

Related